🔮 OOTWOracle · All predictions · Odds sheet · Track record · Benchmark

No federal rescheduling of psilocybin or MDMA occurs in 2026.

Predicted 2026-07-05 · Resolves 2026-12-31 · legislation · USA
82%
ORACLE CONFIDENCE
⏳ Pending
Every outcome is scored publicly in the ledger.

The DEA (Drug Enforcement Administration, the federal agency that enforces drug laws) has the power to move a drug out of Schedule I without Congress acting — but it almost always waits for the FDA to approve a medical use first. Since no approval is coming in 2026, the DEA almost certainly won't act either. That means psilocybin and MDMA remain in the same legal bucket as heroin through the end of 2026.

Resolution rule: YES if, as of 2026-12-31, neither psilocybin nor MDMA has been moved out of Schedule I via a final or interim final DEA rule published on federalregister.gov during calendar year 2026. NO if any such rescheduling rule is published. Source: federalregister.gov (search DEA scheduling actions). Check date: 2026-12-31.

The DEA will not reschedule without an FDA-approved indication, and no approval is pending for 2026. Consensus across dea_officer, legislator, and fda_reviewer agents; the sole dissent (veterans_advocate) argues for legislative momentum, not actual rescheduling, so it does not undercut the core claim.

5 new falsifiable predictions, every day at 12:05 PM ET.
Get tomorrow's Oracle →